The New England Journal of Medicine
e-mail icon  FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |    Advanced Search
Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe
 
Correspondence
PreviousPrevious
Volume 356:963-965 March 1, 2007 Number 9
NextNext

Islet Transplantation

Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

 Sign up for free e-toc
 

This Article
-Full Text
- PDF
-PDA Full Text
-Purchase this article

Tools and Services
-Add to Personal Archive
-Add to Citation Manager
-Notify a Friend
-E-mail When Cited
-E-mail When Letters Appear

More Information
-Related Article
 by Shapiro, A.M. J.
-PubMed Citation
To the Editor: Shapiro et al. (Sept. 28 issue)1 report that in patients with type 1 diabetes who have refractory hypoglycemia, islet transplantation using the Edmonton protocol most often provides endogenous insulin secretion (basal C-peptide secretion, ≥0.3 ng per milliliter) without insulin independence but that this partial beta-cell function provides protection against severe hypoglycemia. Several aspects of this report warrant comment. First, the authors do not state the frequency of hypoglycemia in the recipients before islet transplantation, nor do they report the frequency of hypoglycemia in control subjects. The actual reduction in the risk of severe hypoglycemia is therefore unclear. . . . [Full Text of this Article]




HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  HELP  |  beta.nejm.org

Comments and questions? Please contact us.

The New England Journal of Medicine is owned, published, and copyrighted © 2008 Massachusetts Medical Society. All rights reserved.